BETHESDA, Md. -- New research conducted at the Uniformed Services University of the Health Sciences (USU) suggests that it may be possible to develop a vaccine that protects against the myriad strains of the HIV virus. HIV is extremely variable, so an effective vaccine may need to stimulate the body to produce cross-reactive antibodies that will neutralize multiple viral strains. These results demonstrate that induction of truly broad-spectrum neutralizing antibodies may be an achievable goal. This groundbreaking study titled: Extensively Cross-Reactive Anti-HIV-1 Neutralizing Antibodies Induced by gp140 Immunization appears this week in the Early Edition of Proceedings of the National Academy of Sciences http://www.pnas.org/papbyrecent.shtml.

To be effective, an HIV vaccine must induce the body to produce cross-reactive antibodies that can neutralize multiple strains. USU Professors CAPT Gerald Quinnan, Jr., M.D., USPHS, and Christopher Broder, Ph.D., and their colleagues at USU attempted to elicit these broad-range antibodies in an animal model by immunizing with a particular HIV-1 surface protein, designated R2 gp140, and an immune response-boosting component. The researchers tested antibodies generated by the immunizations to determine their effectiveness in neutralizing the infectivity of a variety of HIV-1 strains. Antibodies produced as a result of immunization neutralized all 48 strains of HIV-1 tested. The results are encouraging for vaccine development, because they showed that it is possible to elicit a broad-spectrum antibody response.